$TYME News

Last published 3y ago

3y agoTYMETyme, Inc. - Appeal, AffirmedUS Patent Trial and Appeal Board
4y agoSYRS TYMESyros and Tyme Technologies Announce Stockholder Approval of MergerGlobeNewswire-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- CAMBRIDGE, Mass. and BEDMINSTER, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a le
4y agoSYRS TYMESyros and Tyme Technologies Announce Stockholder Approval of MergerBusiness Wire-- Combined Company to Trade on Nasdaq Under Ticker "SYRS" ---- Syros Announces 1-for-10 Reverse Stock Split of Common Stock -- Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes,
4y agoTYMETYME Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote "FOR" Proposed Merger of Syros and TymeGlobeNewswireBEDMINSTER, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) ("Tyme" or the "Company"), today announced that independent proxy advisory firms Glass, Lewis & Co. ("Glass Lewis") and Institutional Shareholder Services Inc. (
4y agoSYRS TYMESyros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private PlacementBusiness WireCombined Company Will Operate as Syros Pharmaceuticals and Continue to Advance Syros' Ongoing Clinical Programs Syros Expects to Have Cash Into 2025; At Least a Year Past SELECT-MDS-1 Pivotal Data Now Planning to Initiate Phase 3 Clinical Trial of
4y agoTYMETYME Technologies, Inc. Reports Fourth Fiscal Quarter and Full Year 2022 Financial and Operating ResultsGlobeNewswireBEDMINSTER, N.J., May 25, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its
4y agoTYMETYME Technologies, Inc. Announces Exploration of Strategic OptionsGlobeNewswireBEDMINSTER, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its Board of Directors has
4y agoTYME WSTTYME Technologies, Inc. Announces Changes to its Board of DirectorsBusiness Wire– Industry veteran, Christine D. Baker, joins Board of Directors – Douglas A. Michels appointed Chairman of the Board TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-b
4y agoTYMETYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewswire-- Preclinical results from Georgetown University support that SM-88 is potentially a novel anti-cancer agent in drug resistant estrogen receptor positive breast cancer -- -- Poster presentation April 11, 1:30pm ET; abstract available online -- BED
4y agoTYMETYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating ResultsBusiness Wire– Georgetown University and associated Georgetown Medstar Centers continued enrollment in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor
4y agoTYMETYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ETBusiness WireTYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the Company will report its third quarter 2022 financial results on Friday,
4y agoTYMETYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic CancerBusiness Wire-- SM-88 with MPS arm of Phase 2/3 platform trial in metastatic pancreatic cancer discontinued for futility on primary endpoint of overall survival – TYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company dev
4y agoTYMETYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual ConferenceBusiness WireTYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business
4y agoTYMETYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 InfectionsBusiness Wire-- TYME-19 demonstrated an antiviral effect against SARS CoV-2 in human lung epithelial cells, a model frequently used for drug screening for antiviral efficacy -- -- Completed toxicity studies with TYME-19 that are expected to enable an Investigatio
4y agoTYMETYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers SymposiumBusiness Wire-- Oral SM-88 is an investigational cancer metabolism-based therapy that has demonstrated clinical responses across 15 different types of solid tumors and hematologic cancers – -- Prestigious conference features new, innovative findings in gastroin
5y agoTYMETYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating ResultsBusiness Wire– First patient dosed in Phase II OASIS trial evaluating the potential benefits of oral SM-88 for patients with metastatic HR+/HER2- breast cancer after treatment with a CDK4/6 inhibitor – – PanCAN Precision Promise trial to add five new sites
5y agoTYMETYME Technologies, Inc. to Present at Jefferies London Healthcare ConferenceBusiness WireTYME Technologies, Inc. (NASDAQ:TYME) (the Company or TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Jonathan Eckard, Chief Business
5y agoTYMETYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ETBusiness WireCompany to report its second quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that th
5y agoTYMETYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 InhibitorBusiness Wire-- Novel oral approach aimed at disrupting cancer metabolism in metastatic HR+/HER2- breast cancer – -- HR+/HER2- represents 73% of diagnoses and is the largest subtype of breast cancer1 – -- Breast cancer patients from prior first-in-human st
5y agoTYMETYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry ConferencesBusiness WireTYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that Richie Cunningham, Chief Executive Officer, and Frank Porfido, Chief Financi
5y agoTYMETYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating ResultsBusiness Wire– Completed strategic review, identifying breast cancer, second-line pancreatic cancer, high-risk sarcomas as priority clinical settings – - Announced OASIS breast cancer trial, a multicenter Phase II single-arm, open-label study of SM-88 used wi
5y agoTYMETYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ETBusiness WireCompany to report its first quarter fiscal 2022 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the
5y agoBEKE DYAI EDU ITRM+1Thinking about buying stock in Tyme Technologies, New Oriental Education, Dyadic International, KE Holdings, or Iterum Therapeutics?PR NewswireNEW YORK, July 27, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TYME, EDU, DYAI, BEKE, and ITRM. T
5y agoCLSK DYNT LAC MOGO+1Thinking about buying stock in Dynatronics, Tyme Technologies, Lithium Americas, CleanSpark, or Mogo?PR NewswireNEW YORK, July 26, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DYNT, TYME, LAC, CLSK, and MOGO. T
5y agoTYMETyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat CancerBusiness WireTyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional paten
5y agoTYMETyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial ResultsBusiness Wire– Comprehensive strategic review identified breast cancer as a priority indication for development, a focus on second-line pancreatic cancer, and continuation of trial in high-risk sarcomas – Recently appointed acting Chief Medical Officer and in
5y agoTYMETYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ETBusiness Wire– Company to report conclusions from its comprehensive strategic review, outline its updated business plan and report its fiscal year 2021 financial results TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "TYME"), an emerging biotechnology
5y agoTYMETYME Appoints Frank L. Porfido as Chief Financial OfficerBusiness Wire- Established executive with over 25 years of strategic financial leadership experience across small to large-size clinical and commercial-stage Pharma companies TYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "Tyme"), an emerging biotechnol
5y agoTYMETYME Announces Abstract Selected for Publication at the 2021 American Society of Clinical Oncology Annual MeetingBusiness WireTYME Technologies, Inc. (NASDAQ:TYME) (the "Company" or "Tyme"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that its abstract featuring data from the Company's investigational therapy, SM-8
5y agoTYMETYME Announces Appointment of Dr. Jan M Van Tornout as Acting Chief Medical OfficerBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the appointment of Jan M Van Tornout, MD, MSc, as acting Chief Medical Officer, effective April 1, 2021. Dr. Van Tornout will provide leadership and direction for all medical and related preclinical programs in developme ...
5y agoKALV HTBX TYME ONTX+1Global Human Papillomavirus (HPV) Vaccine Market Could Exceed $12 Billion By 2027PR NewswireThe incidence of cancer is increasing every year and it has been the major factor for the growth of the cancer vaccines market. Healthcare physicians ...
5y agoTYMETYME Announces Closing of $100 Million Registered Direct Offering of Common StockBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that today it closed its previously announced registered direct offering of 40,000,000 shares of its common stock, par value $0.0001 per share, at a purchase price of $2.50 per share, priced at-the-market under Nasdaq rules. T ...
5y agoTYMETYME Provides Business Update and Announces Third Quarter Fiscal 2021 Financial and Operating ResultsBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its third quarter ended December 31, 2020. During the quarter, TYME continued to build its leadership team with the announcement of Richie Cunningham as the new CEO; the Company continued to ...
5y agoTYMETYME Announces $100 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq RulesBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), today announced that it has entered into definitive agreements with several healthcare-focused institutional and other institutional investors for the sale of an aggregate of 40,000,000 shares of its common stock at a purchase price of ...
5y agoTYMETYME Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 InfectionsBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is dir ...
5y agoTYMEOral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer - NCT04720664ClinicalTrials.govObjective Response Rate (ORR), Duration of Response (DOR), Progression Free Survival (PFS), (and 2 more...)
5y agoTYMENew patent application published for: Transdermal FormulationsUS Patent Applications (USPTO)
5y agoTYMETYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers SymposiumBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in patients with metastatic pancreatic cancer, has been selected for poster presentation at the American Society of Clinical O ...
5y agoTYMETYME Builds Leadership Team with Announcement of New CEOBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that, effective November 24, 2020, Steve Hoffman will remain in the role of Chairman of the board of directors and continue as the Company’s Chief Science Officer, after a successful tenure as Chief Executive Officer since 20 ...
5y agoTYMENew patent application published for: Compositions and Methods for Treating CancerUS Patent Applications (USPTO)
6y agoTYMETYME Provides Business Update and Announces Second Quarter Fiscal 2021 Financial and Operating ResultsBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its second quarter ended September 30, 2020. During the quarter, TYME revealed a potential new therapeutic approach in the fight against COVID-19; was granted orphan drug designation for SM- ...
6y agoTYMETyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020Business WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on mul ...
6y agoTYMETYME’s Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New DrugsBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that the final results of its SM-88 Phase II Prostate Cancer study designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with non-metastatic biochemical recurrent prostate cancer, was published on Se ...
6y agoTYMETyme Technologies to Present at BioNJ’s 10th Annual BioPartnering Conference on October 6, 2020Business WireNEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team will present at the BioNJ 10th Annual BioPartnering Conference on Tuesday, October 6, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportuni ...
6y agoTYMETyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020Business WireNEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opp ...
6y agoTYMETyme Technologies to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020Business WireNEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will participate at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020. The Company will present its corporate overview for 2020 with a special focus on multiple growth oppo ...
6y agoTYMETYME’s Oncology Research Reveals Potential New Oral Therapy TYME-19 in the Fight Against COVID-19Business WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced a potential new approach to treating COVID-19 using a metabolic agent, TYME-19. TYME-19 is a synthetic bile acid, a family of metabolic agents that the Company also uses in its anticancer product, TYME-18. Because of its expe ...
6y agoTYMETyme Technologies to Present at the 2020 CHINABIO® Partnering ForumBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will present at the 2020 Cross-Border Healthcare Webinar Series on Wednesday, August 26, 2020. The Company will present its corporate overview with a focus on:
6y agoTYMETYME Announces Appointment of John Rothman, Ph.D. to Executive Vice President, Product DevelopmentBusiness WireBEDMINSTER, N.J.--(BUSINESS WIRE)--Tyme Technologies, Inc. (NASDAQ: TYME, an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the appointment of John Rothman Ph.D. as Executive Vice President, Product Development.
6y agoTYMENew patent application published for: Pharmaceutical Compositions and MethodsUS Patent Applications (USPTO)